Neurostimulation - Advanced Technologies and Global Market (2009 - 2014)

Report Overview

Table of Contents

2942.47

Select License Type

£2,942.47	Electronic License Electronic License An electronic version (mostly PDF, but can be Excel or PPT), which is either available for immediate download or will be sent via email by the Publisher of the report. The licencing for an electronic version is for use by the purchaser ONLY.
£3,575.26	Site License Site License An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is intended for use by more than one individual, across for example, a site, an office, or a division or country.
£4,524.45	Corporate License Corporate License An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is/are intended for use by an organisation in its entirety. For example, if reports are put on an Intranet or if they are distributed or used by more than one office, division, or country operation, then a Corporate Licence is required.
£3,258.87	Hard Copy License Hard Copy License As described. Hard copy reports are dispatched in the post/mail. However, the majority of our reports are in PDF and are either available for immediate download or they are sent by email within hours of purchase.

£2,942.47	Add to Wishlist
Change Currency	GBP EURO USD

Market	Healthcare and Medical
Report Type	Market Research
Country	Global
Published	9 September 2009
Number of Pages	107
Report Delivery	Download
Delivery Lead Time	Immediate
Publisher	Markets&Markets

The global market for neurostimulation products is expected to be worth $3.6 billion in 2009, growing at a CAGR of 22.7%, driven by the multiple treatment applications of neurostimulation products, and the emergence of venture capital in the industry.

Neurostimulation is used for the treatment of several debilitating conditions, including major treatment-resistant depression, epilepsy, gastroparesis, hearing loss, incontinence, chronic pain, Parkinson's disease, and essential tremors. Neurostimulation systems provide an improved lifestyle alternative to many patients who do not obtain relief from standard drug and invasive surgical therapy.

The neurostimulation market is driven mainly by technology advancements, rising consumer awareness, rising age-related neurological disorders, improved clinical outcomes, long-term cost-effectiveness, increased FDA approvals for clinical trials, and the development of sophisticated implantable neurostimulation devices. Currently, there is a huge influx of new players entering into the market, thus leading to increased investments and R&D activities.

Implantable neurostimulation devices are increasingly being used for the treatment of a number of chronic disorders such as pain management and epilepsy. Manufacturers are employing developments in low-power semiconductor design, improved manufacturing procedures, and longer battery life for such devices to offer effective, efficient, and long-lasting neurostimulation products. Innovative products such as closed-loop system neurostimulator are designed to continuously stimulate the nervous system.

SCOPE AND FORMAT

The report analyzes the global biomarker market into the following segments:

• Product Market (spinal cord stimulator, deep brain stimulator, vagus nerve stimulator, sacral nerve stimulator, and gastric electrical stimulator )
• Application Market (Alzheimer's, Parkinson's, chronic heart failure, essential tremors, eye disorders, paralysis, obesity, and other medical conditions )
• Technology Market (minimally-invasive and non-invasive stimulation technology)

The market data consists of aggregate sales figures of all neurostimulation submarkets. It analyzes the market aspects of new neurostimulation technologies and product launches; sourcing key market developments from the top companies that it profiles. The report also analyzes the documented claims and the neurostimulation technology patents approved over the last five years to provide an in-depth understanding of neurostimulation product and applications.

What makes our report unique?

The existing studies and third-party market reports do not provide a comprehensive understanding of the neurostimulation market. The critical markets within this broader field are also not analyzed. This report gives a detailed analysis of the overall market as well as its most critical micro-markets, which have so far remained unexplored. In addition to the comprehensive information on the macro-markets, the report provides market data for up to five levels of the micro-markets under these identified macro markets. Other reports cover only the major technologies or products; and miss out subsequent micro levels.

Key questions answered

• Which are the high growth markets segments in terms of products, applications, and technology?
• What are the market forecasts and estimates from the period 2009-14?
• What are the major drivers and opportunities in the market?
• What is the competitive outlook, what are the major products and applications, who are the major players in the market segments?

Speak to an Advisor

Call us on
+44 (0) 203 086 8600

Select License Type

£2,942.47	Electronic License Electronic License An electronic version (mostly PDF, but can be Excel or PPT), which is either available for immediate download or will be sent via email by the Publisher of the report. The licencing for an electronic version is for use by the purchaser ONLY.
£3,575.26	Site License Site License An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is intended for use by more than one individual, across for example, a site, an office, or a division or country.
£4,524.45	Corporate License Corporate License An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is/are intended for use by an organisation in its entirety. For example, if reports are put on an Intranet or if they are distributed or used by more than one office, division, or country operation, then a Corporate Licence is required.
£3,258.87	Hard Copy License Hard Copy License As described. Hard copy reports are dispatched in the post/mail. However, the majority of our reports are in PDF and are either available for immediate download or they are sent by email within hours of purchase.

£2,942.47	Add to Wishlist
Change Currency	GBP EURO USD

1. INTRODUCTION
1.1. KEY TAKE-AWAYS
1.2. REPORT DESCRIPTION
1.3. MARKETS COVERED
1.4. STAKEHOLDERS
2. THE NERVOUS SYSTEM
2.1. TYPES OF NERVOUS SYSTEM DISORDERS
2.2. BRAIN DISORDERS
2.2.1. Seizures/epilepsy
2.2.2. Alzheimer's Disease
2.3. SACRAL NERVE DISORDERS
2.4. NEUROSTIMULATION TREATMENTS FOR NEURO-DISORDERS
3. MARKET OVERVIEW OF GLOBAL NEUROSTIMULATION MARKET
3.1. DEFINING THE NEUROSTIMULATION PRODUCT MARKET
3.2. VALUE CHAIN ANALYSIS FOR NEUROSTIMULATION MARKET
3.2.1. DEMAND-SIDE DRIVERS
3.2.1.1. Longer lasting effect and shorter hospital stays
3.2.1.2. Minimally-invasive technology
3.2.1.3. Caters to the needs of the aging population
3.2.2. SUPPLY-SIDE DRIVERS
3.2.2.1. New market entrants and technology developments
3.2.2.2. Extensive marketing dynamics
3.2.3. RESTRAINTS
3.2.3.1. High cost of treatment and lack of surgical skill
3.2.3.2. Post-treatment side-effects and prolonged regulatory approvals
3.2.4. OPPORTUNITIES
3.2.4.1. Increasing awareness of neurostimulation in developing countries
3.2.4.2. Gaps in the demand and supply cycle
3.2.5. KEY COMPETITIVE POINTS
3.2.5.1. Improved outcomes at competitive prices
3.2.5.2. Better brand advertising for treatments and products
3.3. PRODUCT LIFECYCLE & MARKET DYNAMICS
3.3.1. Promotional strategies
3.3.2. Channel distribution strategies
3.4. DEFINING THE NEUROSTIMULATION APPLICATIONS MARKET
3.5. NEUROSTIMULATION TECHNOLOGY MARKET
3.5.1. SPINALCORD STIMULATOR DRIVING THE NEUROSTIMULATION PRODUCT MARKET
3.5.2. ALZHEIMER'S AND PARKINSON'S DRIVING THE NEUROSTIMULATION APPLICATIONS MARKET
4. GLOBAL NEUROSTIMULATION PRODUCT MARKET
4.1. DRIVERS
4.1.1. PORTABILITY, USER-FRIENDLINESS, & WIDE-RANGING APPLICATIONS
4.1.2. INCREASING INTEREST OF VENTURE CAPITAL FIRMS
4.1.3. EXTENSIVE PROMOTIONAL STRATEGIES OF MAJOR MARKET PLAYERS
4.2. SPINAL CORD STIMULATOR
4.2.1. DRIVERS
4.2.1.1. High efficiency in the treatment of chronic pain
4.2.1.2. Cost benefits of spinal cord stimulation
4.2.2. BONE GROWTH STIMULATOR
4.2.3. SPINAL CORD FUSION STIMULATOR
4.3. DEEP BRAIN STIMULATOR
4.3.1. DRIVERS
4.3.1.1. Risk-less & flexible alternative to surgery
4.4. VAGUS NERVE STIMULATOR
4.5. SACRAL NERVOUS STIMULATOR
4.5.1. DRIVERS
4.5.1.1. Increase in incidence of urinal and incontinence disorders
4.5.1.2. Shortening of surgical time increases revenues for stakeholders
4.6. GASTRIC ELECTRICAL STIMULATOR
4.6.1. DRIVERS & RESTRAINTS
4.6.1.1. Advantages over conventional treatment
4.6.1.2. Gastric stimulation requires special surgical expertise
5. NEUROSTIMULATION APPLICATION MARKET
5.1. DRIVERS & RESTRAINTS
5.1.1. ADVANTAGES OVER CONVENTIONAL SURGERY
5.1.2. INCREASE IN AGING POPULATION
5.1.3. COST FACTOR & INSUFFICIENT EXPERTISE
5.2. ALZHEIMER'S DISEASE
5.2.1. DRIVERS
5.2.1.1. Memory improvement & fewer side-effects
5.2.1.2. Absence of an alternate cure for Alzheimer's
5.3. PARKINSON'S DISEASE
5.4. PAIN
5.4.1. ACUTE PAIN
5.4.2. CHRONIC PAIN
5.4.2.1. Drivers
5.4.2.2. Migraine
5.4.2.3. Other chronic pain
5.5. CHRONIC HEART FAILURE (CHF)
5.5.1. DRIVERS
5.6. STROKE
5.6.1. EPILEPSY
5.6.2. DEPRESSION
5.6.2.1. Drivers & Restraints
5.6.3. OTHERS STROKES
5.7. PARALYSIS
5.8. OBESITY
5.8.1. DRIVERS
5.8.1.1. Increased accuracy in treating morbid obesity
5.8.1.2. Reduced cost of hospital stays
5.9. ESSENTIAL TREMORS
5.10. EYE DISORDERS
5.10.1. SECOND SIGHT DISORDERS
5.10.2. OTHER EYE DISORDERS
5.11. OTHER NEUROSTIMULATION APPLICATIONS
5.12. GASTROPARESIS
5.13. INCONTINENCE
6. GLOBAL NEUROSTIMULATION TECHNOLOGY MARKET
6.1. DRIVERS
6.2. MINIMALLY-INVASIVE STIMULATION
6.2.1. MAGNETIC NERVE STIMULATION
6.2.1.1. Drivers
6.2.1.1.1. Better treatment than anti-depression drugs
6.2.1.1.2. Technology developments supporting market growth
6.2.2. TRANSCUTANEOUS ELECTRICAL NEUROSTIMULATION
6.2.3. OTHERS MINIMALLY-INVASIVE NEUROSTIMULATION TECHNOLOGY
7. GEOGRAPHIC ANALYSIS
7.1. NORTH AMERICA
7.2. EUROPE
7.3. ASIA
7.4. ROW
8. COMPETITIVE LANDSCAPE
9. NEUROSTIMULATION PATENT ANALYSIS
10. NEUROSTIMULATION COMPANY PROFILES
10.1. CYBERONICS, INC.
10.2. DYNATRONICS
10.3. ELEKTA AB
10.4. ENTEROMEDICS, INC.
10.5. GI DYNAMICS
10.6. H. LUNDBECK
10.7. IMPULSE DYNAMICS
10.8. INNOVATIVE NEUROTRONICS, INC.
10.9. INTEGRA LIFE SCIENCES HOLDINGS CORPORATION
10.10. MEDTRONIC, INC
10.11. NDI MEDICAL
10.12. NEURONETICS, INC.
10.13. NEUROPACE
10.14. NEUROTECH
10.15. NEXSTIM
10.16. RS MEDICAL
10.17. ST. JUDE MEDICAL, INC.
10.18. SYNAPSE BIOMEDICAL
10.19. THE MAGSTIM COMPANY LIMITED
10.20. VERTIS NEUROSCIENCE
APPENDIX

LIST OF TABLES

TABLE 1 GLOBAL NEUROSTIMULATION MARKET, BY PRODUCT 2007 - 2014 ($MILLIONS)
TABLE 2 GLOBAL NEUROSTIMULATION PRODUCT MARKET, BY GEOGRAPHY 2007 - 2014($ MILLIONS)
TABLE 3 GLOBAL SPINAL CORD STIMULATOR MARKET, BY PRODUCT 2009 - 2014 ($ MILLIONS)
TABLE 4 GLOBAL SPINAL CORD STIMULATOR MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 5 GLOBAL BONE GROWTH STIMULATOR MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 6 GLOBAL SPINAL CORD FUSION STIMULATOR MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 7 GLOBAL DEEP BRAIN STIMULATOR MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 8 GLOBAL VAGUS NERVE STIMULATOR MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 9 GLOBAL SACRAL NERVE STIMULATOR MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 10 GLOBAL GASTRIC ELECTRICAL STIMULATOR MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 11 GLOBAL NEUROSTIMULATION APPLICATIONS MARKET 2007 - 2014 ($ MILLIONS)
TABLE 12 GLOBAL NEUROSTIMULATION APPLICATIONS MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 13 GLOBAL ALZHEIMER'S NEUROSTIMULATION MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 14 GLOBAL PARKINSON'S NEUROSTIMULATION MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 15 GLOBAL NEUROSTIMULATION PAIN APPLICATIONS MARKET 2007 - 2014 ($ MILLIONS)
TABLE 16 GLOBAL PAIN NEUROSTIMULATION MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 17 GLOBAL ACUTE PAIN NEUROSTIMULATION MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 18 GLOBAL CHRONIC PAIN NEUROSTIMULATION MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 19 GLOBAL CHRONIC PAIN NEUROSTIMULATION MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 20 GLOBAL MIGRAINE NEUROSTIMULATION MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 21 GLOBAL OTHER CHRONIC PAIN NEUROSTIMULATION MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 22 GLOBAL CHRONIC HEART FAILURE NEUROSTIMULATION MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 23 GLOBAL NEUROSTIMULATION APPLICATIONS MARKET FOR STROKE, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 24 GLOBAL NEUROSTIMULATION APPLICATIONS MARKET FOR STROKE, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 25 GLOBAL NEUROSTIMULATION MARKET FOR EPILEPSY, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 26 GLOBAL NEUROSTIMULATION MARKET FOR DEPRESSION, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 27 GLOBAL NEUROSTIMULATION MARKET FOR OTHER STROKES, BY GEOGRAPHY 2007 - 2014($ MILLIONS
TABLE 28 GLOBAL NEUROSTIMULATION MARKET FOR PARALYSIS, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 29 GLOBAL NEUROSTIMULATION MARKET FOR OBESITY, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 30 GLOBAL NEUROSTIMULATION MARKET FOR ESSENTIAL TREMORS, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 31 GLOBAL NEUROSTIMULATION APPLICATIONS MARKET FOR EYE DISEASES 2007 - 2014 ($ MILLIONS)
TABLE 32 GLOBAL NEUROSTIMULATION MARKET FOR EYE DISEASES, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 33 GLOBAL NEUROSTIMULATION MARKET FOR SECOND SIGHT, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 34 GLOBAL NEUROSTIMULATION MARKET FOR OTHER EYE DISORDERS, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 35 GLOBAL OTHER NEUROSTIMULATION APPLICATIONS MARKET 2007 - 2014($ MILLIONS)
TABLE 36 GLOBAL OTHER NEUROSTIMULATION APPLICATIONS MARKET, BY GEOGRAPHY 2007 - 2014($ MILLIONS)
TABLE 37 GLOBAL NEUROSTIMULATION MARKET FOR GASTROPARESIS, BY GEOGRAPHY 2007 - 2014($ MILLIONS)
TABLE 38 GLOBAL NEUROSTIMULATION MARKET FOR INCONTINENCE, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 39 GLOBAL NEUROSTIMULATION TECHNOLOGY MARKET, BY PRODUCT 2007 - 2014 ($ MILLIONS)
TABLE 40 GLOBAL NEUROSTIMULATION TECHNOLOGY MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 41 GLOBAL MINIMALLY-INVASIVE NEUROSTIMULATION TECHNOLOGY MARKET, BY PRODUCT 2007 - 2014 ($ MILLIONS)
TABLE 42 GLOBAL MINIMALLY-INVASIVE NEUROSTIMULATION TECHNOLOGY MARKET, BY GEOGRAPHY 2007 - 2014($ MILLIONS)
TABLE 43 GLOBAL MINIMALLY-INVASIVE MAGNETIC NERVE NEUROSTIMULATION TECHNOLOGY MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 44 GLOBAL MINIMALLY-INVASIVE TRANSCUTANEOUS ELECTRICAL NEUROSTIMULATION TECHNOLOGY MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 45 GLOBAL OTHER MINIMALLY-INVASIVE NEUROSTIMULATION MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 46 REGULATORY APPROVALS IN THE NEUROSTIMULATION MARKET (2008-2009)
TABLE 47 NEW PRODUCT DEVELOPMENTS IN THE NEUROSTIMULATION MARKET (2008-2009)
TABLE 48 NEUROSTIMULATION PATENTS FILED FROM 2004 TO JUNE 2009

LIST OF FIGURES

FIGURE 1 NEUROSTIMULATION PRODUCT MARKET BY TOTAL MARKET SIZE (2007 - 2014)
FIGURE 2 VALUE CHAIN ANALYSIS FOR NEUROSTIMULATION MARKET
FIGURE 3 PRODUCT LIFE CYCLE GRAPH OF NEUROSTIMULATION MARKET
FIGURE 4 NEUROSTIMULATION APPLICATIONS MARKET
FIGURE 5 NEUROSTIMULATION PRODUCT MARKET SHARE AND MARKET GROWTH MATRIX ANALYSIS
FIGURE 6 NEUROSTIMULATION APPLICATION MARKET SHARE AND MARKET GROWTH RATE MATRIX ANALYSIS 2009
FIGURE 7 GEOGARPHICAL MARKET ANALYSIS OF THE PRODUCT MARKET (2009)
FIGURE 8 REGULATORY APPROVALS IN THE NEUROSTIMULATION MARKET (2008-2009)
FIGURE 9 NEW PRODUCT LAUNCHES IN THE NEUROSTIMULATION MARKET (2008-2009)
FIGURE 10 NEUROSTIMULATION PATENTS FILED WORLDWIDE (2004 TO JUNE 2009)
FIGURE 11 NEUROSTIMULATION PATENTS FILED WORLDWIDE FOR DIFFERENT CATEGORIES (2004 TO JUNE 2009)
FIGURE 12 NEUROSTIMULATION PATENTS FILED IN NORTH AMERICA (2004 TO JUNE 2009)
FIGURE 13 NEUROSTIMULATION PATENTS FILED IN EUROPE (2004 TO JUNE 2009)
FIGURE 14 NEUROSTIMULATION PATENTS FILED IN ASIA (2004 TO JUNE 2009)

Change Currency

GBP

EURO

USD

Last Viewed

Neurostimulation - Advanced Technologies and Global Market (2009 - 2014)

Sequoia Capital Operations LLC - Clean Technology - Investment Profile

ArcLight Capital Partners, LLC - Clean Technology - Investment Profile

Respiratory and Pulmonary System Chronic Obstructive Pulmonary Disease Therapy Area Pipeline Report

Merger & Acquisition Deal Analysis - Cancen Oil Canada Acquires Additional Facility In British Columbia

Healthcare and Medical Company Profiles

Healthcare and Medical Company Profiles contain up to date financial, strategic, operational, SWOT analysis and product information on the activities of thousands of healthcare and medical companies.

Become an Affiliate

Do you manage an industry specific website or blog? Are you looking to monetise your web traffic further? Are you a B2B website?

Why not offer your visitors industry specific strategic market reports and company profiles? Our Affiliate Program enables you to provide quality content on your website and to earn money from passing on visitors to our website. If a sale is made from your visitor, you earn commission (a fixed percentage of the price of a product).

Custom Research

Cannot find what you need? We can tailor a report for you. Complete the Custom Research Form and we will provide a quote.

Healthcare and Medical	Type	Keywords Phrase All Words Any Word
Microsoft Windows users can hold the CTRL Key to select more than one sector or country at a time. Apple users can hold the CMD Key to do the same.	Country	Industry Sector
Publisher	Order By Relevance Date	Published In

Neurostimulation - Advanced Technologies and Global Market (2009 - 2014)

Select License Type

Speak to an Advisor

Select License Type

Table of Contents

Change Currency

Last Viewed

Healthcare and Medical Company Profiles

Become an Affiliate

Custom Research

News

Market Insights

Companies And Markets

Customer Support

Corporate Accounts

Contact Details

Contrast settings

Text size settings

All
Afghanistan
Africa
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antigua and Barbuda
Argentina
Armenia
Aruba
Asia
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia-Herzegovina
Botswana
Bouvet Island
Brazil
British Virgin Islands
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Caribbean
Cayman Islands
Central African Republic
Central America
Central Europe
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Conch Republic
Cook Islands
Costa Rica
Croatia
Cuba
Cyprus
Czech Republic
Democratic Republic of Congo
Denmark
Djibouti
Dominica
Dominican Republic
Eastern Europe
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Europe
Falkland Islands
Faroe Islands
Fiji
Finland
France
French Guiana
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Global
Greece
Greenland
Grenada
Guadeloupe (French)
Guam (USA)
Guatemala
Guernsey
Guinea
Guinea Bissau
Guyana
Haiti
Heard Island and McDonald Islans
Holy See
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Ivory Coast
Ivory Coast (Cote D`Ivoire)
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Kurdistan
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macau
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique (French)
Mauritania
Mauritius
Mayotte
Mexico
Micronesia
Middle East
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
Netherlands Antilles
New Caledonia (French)
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
North America
North Korea
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn Island
Poland
Polynesia (French)
Portugal
Puerto Rico
Qatar
Reunion
Romania
Russia
Rwanda
Saint Barthelemy
Saint Helena
Saint Kitts and Nevis
Saint Lucia
Saint Martin
Saint Pierre and Miquelon
Saint Vincent and Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Scandinavia
Schengen countries
Senegal
Serbia and Montenegro
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South America
South Georgia and the South Sandwich Islands
South Korea
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen Islands
Swaziland
Sweden
Switzerland
Syria
Taiwan
Tajikistan
Tanzania
Thailand
Timor-Leste (East Timor)
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela
Vietnam
Virgin Islands
Wallis and Futuna Islands
Western Sahara
Yemen
Zambia
Zimbabwe

All
Aerospace
Agriculture, Farming & Raw Materials
Automotive and Parts
Business Services
Chemicals
Construction
Consumer Goods
Defence
Energy and Utilities
Environmental
Finance and Banking
Food and Drink
Healthcare and Medical
Industrial
Information Technology
Leisure
Logistics
Media
Paper and Packaging
Publishing and Printing
Real Estate
Retail
Security
Telecommunications
Textiles and Clothing
Transportation
Travel